dc.contributor.author | Scherrer, E | |
dc.contributor.author | Rau, R | |
dc.contributor.author | Lorenzi, M | |
dc.contributor.author | Shui, I | |
dc.contributor.author | Townson, S | |
dc.contributor.author | Larkin, J | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2022-08-30T13:33:49Z | |
dc.date.available | 2022-08-30T13:33:49Z | |
dc.date.issued | 2021-03-30 | |
dc.identifier.citation | Future Oncology, 2021, 17 (20), pp. 2683 - 2692 | en_US |
dc.identifier.issn | 1479-6694 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5351 | |
dc.identifier.eissn | 1744-8301 | |
dc.identifier.eissn | 1744-8301 | |
dc.identifier.doi | 10.2217/fon-2021-0154 | |
dc.description.abstract | Aim: Summarize the literature assessing biomarkers in predicting efficacy of anti-PD-1 therapy for patients with high-risk unresectable or metastatic melanoma. Materials & methods: Relevant studies were identified via a systematic literature review. Results: About 334 unique biomarkers or biomarker combinations were identified from 121 citations. Neutrophil-to-lymphocyte ratio was the most frequently studied biomarker, followed by C-reactive protein. Fifty-nine biomarkers were significantly associated with overall survival (OS), 51 with progression-free survival (PFS) and 44 with response. Twenty biomarkers were associated with both OS and PFS; two were associated with OS, PFS and response (MHC-II and tumor mutational burden). Conclusion: Numerous biomarkers could potentially predict the efficacy of anti-PD-1-based therapy for melanoma patients. However, confirmatory studies are needed as well as determination of implications for clinical decision-making. | |
dc.format | Print-Electronic | |
dc.format.extent | 2683 - 2692 | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | FUTURE MEDICINE LTD | en_US |
dc.relation.ispartof | Future Oncology | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.subject | anti-PD-1 inhibitors | |
dc.subject | association | |
dc.subject | biomarkers | |
dc.subject | melanoma | |
dc.subject | systematic literature review | |
dc.subject | Biomarkers, Tumor | |
dc.subject | Clinical Decision-Making | |
dc.subject | Humans | |
dc.subject | Immune Checkpoint Inhibitors | |
dc.subject | Melanoma | |
dc.subject | Patient Selection | |
dc.subject | Programmed Cell Death 1 Receptor | |
dc.subject | Progression-Free Survival | |
dc.subject | Risk Assessment | |
dc.subject | Skin Neoplasms | |
dc.title | Systematic literature review for the association of biomarkers with efficacy of anti-PD-1 inhibitors in advanced melanoma. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-03-12 | |
dc.date.updated | 2022-08-30T10:04:28Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.2217/fon-2021-0154 | en_US |
rioxxterms.licenseref.startdate | 2021-03-30 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/33783230 | |
pubs.issue | 20 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.publication-status | Published | |
pubs.volume | 17 | |
dc.contributor.icrauthor | Larkin, James | |
icr.provenance | Deposited by Mr Arek Surman on 2022-08-30. Deposit type is initial. No. of files: 1. Files: fon-2021-0154.pdf | |